

Dear xxx

Freedom of Information request: Treatment of Breast Cancer (CORP 25/26 – 042)

Thank you for your request for information which the Trust received on 3rd June 2025.

Your Request:

1) *How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:*

- *Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- *Abemaciclib + Fulvestrant*
- *Alpelisib + Fulvestrant*
- *Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide*
- *Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel*
- *Atezolizumab*
- *Capivasertib*
- *Capecitabine as a single agent*
- *Carboplatin + Paclitaxel*
- *Elacestrant*
- *Eribulin as a single agent or in combination*
- *Everolimus + Exemestane*
- *Fulvestrant as a single agent*
- *Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- *Palbociclib + Fulvestrant*
- *Parp Inhibitors (Olaparib/Talazoparib)*
- *Pembrolizumab Monotherapy*
- *Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab*
- *Carboplatin + Paclitaxel + Pembrolizumab*
- *Pertuzumab (Perteja) + Trastuzumab (Herceptin)*
- *Phesgo (Pertuzumab + Trastuzumab in a single injection)*
- *Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)*
- *Ribociclib + Fulvestrant*
- *Sacituzumab Govitecan*
- *Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent*
- *Trastuzumab deruxtecan (Enhertu)*
- *Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel*
- *Trastuzumab emtansine (Kadcyla)*
- *Any other active systemic anti-cancer therapy*
- *Aromatase Inhibitor as a single agent*

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.

- 2) *Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.*

Please find the Trust's response below:

We note the same or a very similar request is being made every few months. To avoid the future use of a Qualified Exemption under Section 14(2) Freedom of Information Act 2000, the Trust suggests that you may wish to revise your periodicity of requests so that a reasonable interval has elapsed to enable the Trust to provide information to you whilst be mindful of its resources in providing such information. We recommend at least 6-9 months between requests.


Section 14(2) - Vexatious or repeated requests:

(2) Where a public authority has previously complied with a request for information which was made by any person, it is not obliged to comply with a subsequent identical or substantially similar request from that person unless a reasonable interval has elapsed between compliance with the previous request and the making of the current request.

- 1) **How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:**

- **Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)**
- **Abemaciclib + Fulvestrant**
- **Alpelisib + Fulvestrant**
- **Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide**
- **Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel**
- **Atezolizumab**
- **Capivasertib**
- **Capecitabine as a single agent**
- **Carboplatin + Paclitaxel**
- **Elacestrant**
- **Eribulin as a single agent or in combination**
- **Everolimus + Exemestane**
- **Fulvestrant as a single agent**
- **Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)**
- **Palbociclib + Fulvestrant**
- **Parp Inhibitors (Olaparib/Talazoparib)**
- **Pembrolizumab Monotherapy**
- **Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab**
- **Carboplatin + Paclitaxel + Pembrolizumab**
- **Pertuzumab (Perteja) + Trastuzumab (Herceptin)**
- **Phesgo (Pertuzumab + Trastuzumab in a single injection)**

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.




- **Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)**
- **Ribociclib + Fulvestrant**
- **Sacituzumab Govitecan**
- **Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent**
- **Trastuzumab deruxtecan (Enhertu)**
- **Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel**
- **Trastuzumab emtansine (Kadcyla)**
- **Any other active systemic anti-cancer therapy**
- **Aromatase Inhibitor as a single agent**

There have been 1075 patients treated for breast cancer with the above systemic anti-cancer therapies. This is the number of unique patients treated with the above, some may have received more than one of drugs/treatments.

2) Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Short Title	Total Participants Recruited
TRAK-ER	6
FAIM	0
CELC-G-301 (A.K.A VIKTORIA 1)	<6
Tropion 05	<6
CAMBRIA-2	6
DYNASTY-Breast02	0
OPTIMA	166
OLYMPIA	8
Concept	10
PARTNER	40
PALLAS	22
SPECTA	19
NATALEE	9
CAPitello - 291	9
D9670C00001 (DESTINY-Breast06)	<6
ZEST	10
TROPION-02	<6
TROPION 03	11
TROPION 04	<6
PAKT	11
AURORA	21
UNIRAD	<6
APHINITY	<6

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Short Title	Total Participants Recruited
COMPLEEMENT	7
Violette	<6
Ipatunity 130	<6
c-TRAK TN	16
VIP-Epi	47
TROPION-01	<6
Phoenix	<6

Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.


You should forward your complaint to:

Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales
2nd Floor
Churchill House
Churchill Way
Cardiff
CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Yours sincerely

**Non Gwilym
Interim Director of Corporate Governance**

Velindre University NHS Trust
2 Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.

